HC Wainwright Reiterates Buy Rating for Femasys (NASDAQ:FEMY)

HC Wainwright reiterated their buy rating on shares of Femasys (NASDAQ:FEMY) in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock.

Separately, Chardan Capital dropped their price target on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Femasys Trading Up 12.1 %

NASDAQ:FEMY opened at $1.57 on Thursday. Femasys has a 12 month low of $0.86 and a 12 month high of $2.12. The firm has a market cap of $35.95 million, a price-to-earnings ratio of -1.94 and a beta of -2.86. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The company’s 50 day moving average is $1.32 and its 200-day moving average is $1.20.

Hedge Funds Weigh In On Femasys

A number of institutional investors and hedge funds have recently bought and sold shares of FEMY. Aljian Capital Management LLC bought a new position in Femasys during the third quarter worth $27,000. XTX Topco Ltd boosted its stake in Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares in the last quarter. Geode Capital Management LLC boosted its stake in Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares in the last quarter. Virtu Financial LLC acquired a new stake in Femasys during the fourth quarter worth $25,000. Finally, Northern Trust Corp boosted its stake in Femasys by 42.6% during the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after buying an additional 37,675 shares in the last quarter. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.